UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 259

Sortiert nach

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of oncology, 2020-11, Vol.31 (11), p.1526-1535

2020

Volltextzugriff (PDF)

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

Leukemia, 2013-06, Vol.27 (6), p.1229-1235

2013

Volltextzugriff (PDF)

Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter

Blood, 2021-10, Vol.138 (15), p.1345-1358

2021

Volltextzugriff (PDF)

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Leukemia, 2013-09, Vol.27 (9), p.1910-1913

2013

Volltextzugriff (PDF)

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Volltextzugriff (PDF)

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT)

Annals of oncology, 2018-10, Vol.29, p.viii301-viii301

2018

Volltextzugriff (PDF)

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

Annals of oncology, 2018-10, Vol.29, p.viii97-viii97

2018

Volltextzugriff (PDF)

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

Bone marrow transplantation (Basingstoke), 2010-05, Vol.45 (5), p.872-876

2010

Volltextzugriff (PDF)

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence

Leukemia, 2009-05, Vol.23 (5), p.892-899

2009

Volltextzugriff (PDF)

Sorafenib (Nexavar® ) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

Leukemia research, 2009-02, Vol.33 (2), p.348-350

2009

Volltextzugriff (PDF)

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

Hematology, Transfusion and Cell Therapy, 2023-10, Vol.45, p.S404-S405

2023

Volltextzugriff (PDF)

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Bone marrow transplantation (Basingstoke), 2009-05, Vol.43 (9), p.669-677

2009

Volltextzugriff (PDF)

Bendamustine in patients with relapsed or refractory multiple myeloma

European journal of medical research, 2010-01, Vol.15 (1), p.13-13

2010

Volltextzugriff (PDF)

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

HemaSphere, 2022-06, Vol.6 (Suppl), p.839-840

2022

Volltextzugriff (PDF)

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

Leukemia, 2009-05, Vol.23 (5), p.983-985

2009

Volltextzugriff (PDF)

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

Annals of oncology, 2010-09, Vol.21 (9), p.1898-1904

2010

Volltextzugriff (PDF)

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases

Bone marrow transplantation (Basingstoke), 2011-05, Vol.46 (5), p.747-755

2011

Volltextzugriff (PDF)

Fludarabine, amsacrine, high-dose cytarabine and 12Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

Bone marrow transplantation (Basingstoke), 2009-12, Vol.44 (12), p.785-792

2009

Volltextzugriff (PDF)

O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome

Leukemia research, 2013-05, Vol.37, p.S10-S10

2013

Volltextzugriff (PDF)

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

Bone marrow transplantation (Basingstoke), 2009-12, Vol.44 (12), p.785-792

2009

Volltextzugriff (PDF)

The Mexican Way: a feasible approach to avoid DMSO toxicity

Bone marrow transplantation (Basingstoke), 2011-03, Vol.46 (3), p.469-471

2011

Volltextzugriff (PDF)

P-210 Azacitidine and DLI as salvage therapy for MDS or AML relapse after allo-SCT induces long-term molecular remissions and increases Tregs

Leukemia research, 2013-05, Vol.37, p.S118-S118

2013

Volltextzugriff (PDF)

Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.OT3-03-02-OT3-03-02

2019

Volltextzugriff (PDF)

C015 Proteome analysis of platelets from patients with myelodysplastic syndrome shows low expression of proteins required for GPIIb/IIIa function and platelet aggregation

Leukemia research, 2009-05, Vol.33, p.S40-S40

2009

Volltextzugriff (PDF)

P170 - NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)

Breast (Edinburgh), 2019-03, Vol.44, p.S73-S74

2019

Volltextzugriff (PDF)

1 – 25 von 259

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(249)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(95)
Life Sciences & Biomedicine
(84)
Humans
(64)
Male
(39)
Female
(36)
Hematology
(29)
Oncology
(28)
Animals
(25)
Middle Aged
(24)
Aged
(22)
Biological And Medical Sciences
(22)
Mice
(22)
Adult
(21)
Medical Sciences
(18)
Anxiety
(17)
Gene Expression
(12)
Gene Expression Profiling
(12)
Hematologic And Hematopoietic Diseases
(11)
Immunology
(11)
Neurosciences
(11)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(38)
Journal Of Clinical Oncology
(28)
Annals Of Oncology
(13)
Cancer Research
(11)
Bone Marrow Transplantation
(7)
Leukemia Research
(7)
Plos One
(7)
Clinical Cancer Research
(5)
Archives Of Physiology And Biochemistry
(4)
Haematologica
(4)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter

Salvage therapy with azacitidine increases regulatory T cells in peripheral blood of patients with AML or MDS and early relapse after allogeneic blood stem cell transplantation

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial

TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT)

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials

5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis

The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence

Sorafenib (Nexavar® ) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MAGNETISMM-3 STUDY

Pegfilgrastim for PBSC mobilization and autologous haematopoietic SCT

Bendamustine in patients with relapsed or refractory multiple myeloma

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B‐CELL MATURATION ANTIGEN (BCMA)‐CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR MAGNETISMM‐3

Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases

Fludarabine, amsacrine, high-dose cytarabine and 12Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome

Fludarabine, amsacrine, high-dose cytarabine and 12 Gy total body irradiation followed by allogeneic hematopoietic stem cell transplantation is effective in patients with relapsed or high-risk acute lymphoblastic leukemia

The Mexican Way: a feasible approach to avoid DMSO toxicity

P-210 Azacitidine and DLI as salvage therapy for MDS or AML relapse after allo-SCT induces long-term molecular remissions and increases Tregs

Abstract OT3-03-02: A phase 2, open-label, single-arm, multi-center study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple-negative breast cancer (TNBC)

C015 Proteome analysis of platelets from patients with myelodysplastic syndrome shows low expression of proteins required for GPIIb/IIIa function and platelet aggregation

P170 - NEOTALA: an open-label, single-arm, multi-center, phase 2 study of talazoparib for neoadjuvant treatment of germline BRCA1/2 mutation patients with early-stage triple negative breast cancer (TNBC)

Suchergebnisse filtern